Prognostic and Predictive Impact of the HER-2/neu Extracellular Domain (ECD) in the Serum of Patients Treated with Chemotherapy for Metastatic Breast Cancer
- 1 July 2004
- journal article
- clinical trial
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 86 (1) , 9-18
- https://doi.org/10.1023/b:brea.0000032919.83803.48
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Elevated Serum HER-2/neu Level Predicts Decreased Response to Hormone Therapy in Metastatic Breast CancerJournal of Clinical Oncology, 2002
- Prognostic significance of serum c-erbB-2 protein in breast cancer patientsBreast Cancer Research and Treatment, 1996
- c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancerEuropean Journal Of Cancer, 1995
- Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.Journal of Clinical Oncology, 1995
- Identification and characterization of c‐erbb‐2 proteins in serum, breast tumor tissue, and sk‐br‐3 cell lineJournal of Clinical Laboratory Analysis, 1995
- Soluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early-stage and advanced breast cancerBritish Journal of Cancer, 1994
- c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast CancerNew England Journal of Medicine, 1994
- Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neuBreast Cancer Research and Treatment, 1992
- HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma.Journal of Clinical Oncology, 1992
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987